Denosumab News and Research

RSS

Denosumab is a fully human monoclonal antibody that targets RANK Ligand and is being investigated for its potential to prevent and treat a broad range of bone disease conditions including osteoporosis, bone metastases and their consequences, cancer treatment-induced bone loss due to hormone ablative therapy, multiple myeloma and bone erosions in rheumatoid arthritis. Denosumab is the first late-stage investigational therapy that specifically inhibits RANK Ligand, an essential mediator of the cells that break down bone.

Study finds link between industry payments to oncologists and non-recommended cancer treatments

Patients with cancer whose oncologist receives payments from industry appear more likely to receive some non-recommended and low value treatments, finds a US study published by The BMJ today.

25 Oct 2023

COVID-19 pandemic fails to deter osteoporosis treatment initiation: New study reveals steady rates

Whether patients with newly diagnosed osteoporosis received delayed pharmacologic treatment due to the COVID-19 pandemic.

18 Sep 2023

New drug could overcome resistance to CDK4/6 inhibitors in breast cancer

Brest cancer is the most common cancer in women. Among breast tumors that spread to other organs (develop metastasis), 70% belong to a variant, called luminal, whose cells are sensitive to the female sex hormones estrogen and progesterone. In fact, the tumor forms when these hormones order the cells to divide.

14 Jul 2023

New treatment for fibrous dysplasia shows promising results in NIH clinical trial

A clinical trial at the National Institutes of Health found that a medication, denosumab, significantly reduced abnormal bone turnover in adults with fibrous dysplasia, a rare disease marked by weak and misshapen bones.

4 Apr 2023

Denosumab may benefit postmenopausal patients with hormone receptor-negative breast tumors and RANK protein expression

The drug denosumab is currently used to treat osteoporosis and bone metastases. For more than a decade, its potential therapeutic benefit in the treatment of breast cancer has also been studied.

7 Mar 2023

Experts provide first framework for treating hypercalcemia of malignancy in adults

Experts provide the first framework for treating a common and life-threatening metabolic complication of cancer known as hypercalcemia of malignancy in the Endocrine Society's new Clinical Practice Guideline.

21 Dec 2022

Researchers discover osteogenetic oligodeoxynucleotide that promotes bone differentiation

Bone tissue homeostasis is maintained by a balance between bone formation by osteoblasts and bone resorption by osteoclasts.

23 May 2022

Advancements in the diagnosis and treatment of prostate cancer are saving more lives

Prostate cancer is the most common type of cancer among men in the United States aside from skin cancer, according to the Centers for Disease Control and Prevention.

8 Sep 2021

Study: One in six men with advanced prostate cancer experiences reduced sense of smell and taste

One in six men being treated for advanced prostate cancer experiences a reduced sense of smell and taste, a symptom that could cause increased anxiety among patients because it is also a side effect of COVID-19, according to Tulane researchers.

16 Mar 2021

Osteoporosis drug increases bone mineral density in the hip and lumbar spine

New research presented at ACR Convergence, the American College Rheumatology's annual meeting, reveals that romosozumab, an osteoporosis drug, produces substantial gains in bone mineral density in the hip and lumbar spine within one year, and that transitioning patients to a potent antiresorptive drug can lead to even more bone density gains.

6 Nov 2020

Some of the main osteoporosis treatments could have a protective effect against COVID-19

Some of the principal treatments for osteoporosis, denosumab, zoledronate and calcium, could have a protective effect against COVID-19 in patients who take them, specifically a 30 to 40% reduction in the rate of infection, according to the results of a joint study by Hospital del Mar, the Hospital del Mar Medical Research Institute (IMIM), Pompeu Fabra University and the Pere Virgili Health Park.

3 Nov 2020

Improving cancer therapies by exploiting drug resistance in cancer

News-Medical talks to Professor David Thomas about his recent research identifying the mechanisms behind cancer cells developing resistance to drugs.

23 Jun 2020

New guidance released for treating patients with osteoporosis during COVID-19 crisis

The Endocrine Society joined a coalition of leading bone health organizations to release guidance for healthcare professionals treating patients with osteoporosis in the era of COVID-19.

8 May 2020

GlobalData highlights low diagnosis and treatment rates of osteoporosis

As World Osteoporosis Day approaches (20 October), it marks a year-long campaign dedicated to raising global awareness of this bone disease. A major unmet need in this space is the low rate of diagnosis and treatment.

18 Oct 2019

$FDA approves new osteoporosis drug for postmenopausal women with high fracture risk$

FDA approves new osteoporosis drug for postmenopausal women with high fracture risk

The U.S. Food and Drug Administration today approved Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk of breaking a bone (fracture).

9 Apr 2019

Benefits of osteoporosis treatment in postmenopausal women outweigh the perceived risks

The benefits of treating osteoporosis in postmenopausal women outweigh the perceived risks, according to a Clinical Practice Guideline issued today by the Endocrine Society. The Society introduced the guideline during a news conference on Monday at ENDO 2019, its annual meeting in New Orleans, La.

25 Mar 2019

New treatment option appears promising for patients with glucocorticoid-induced osteoporosis

About one in every 100 people in the world takes glucocorticoids long term to treat immune-mediated diseases. However, glucocorticoids, such as prednisone, have a side effect -- they induce the bone loss called osteoporosis, causing an estimated yearly bone fracture rate of 5 percent.

27 Apr 2018

$Drug holiday from bisphosphonates for more than two years linked to higher hip fracture risk in women$

Drug holiday from bisphosphonates for more than two years linked to higher hip fracture risk in women

Women who took a drug holiday (temporary or permanent discontinuation of a medicine) from using bisphosphonates for more than two years have a significantly higher risk of a hip fracture compared to others who continued their treatment, according to new research findings presented this week at the 2017 ACR/ARHP Annual Meeting in San Diego.

6 Nov 2017

ACR’s updated guideline provides recommendations on treatment of glucocorticoid-induced osteoporosis

The American College of Rheumatology's updated clinical guideline for the prevention and treatment of glucocorticoid-induced osteoporosis is now available online.

7 Jun 2017

Thyroid cancer patients with bone metastases have worse survival, study finds

When cancer metastases, bone unwittingly offers a friendly place for tumor cell growth--only to have its hospitality betrayed by pathologic fractures, spinal cord compression, the need for bone surgery or irradiation, and an increased risk of death.

17 Apr 2017